Crossbow Therapeutics Doses 1st Patient in Ph 1 Trial of CBX-250
16 Sep 2025 //
PHARMAWEB
Crossbow Picks CBX-663 for Solid and Blood Cancer Treatment
23 Jul 2025 //
BUSINESSWIRE
Crossbow Selects First Development Candidate from its T-cell Engagers
05 Mar 2024 //
GLOBENEWSWIRE
Crossbow Therapeutics Launches with $80 Million in Series A Financing
11 Jul 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support